Premium
Treatment of focal and/or diffuse central serous chorioretinopathy by series of 3 ranibizumab IVT
Author(s) -
GONZALEZ C
Publication year - 2010
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2010.4317.x
Subject(s) - medicine , serous fluid , ranibizumab , ophthalmology , fluorescein angiography , visual acuity , retinal , optical coherence tomography , surgery , bevacizumab , pathology , chemotherapy
Purpose To evaluate the functional, anatomical, vascular flow, effects of intravitreal injections(IVT) for focal and/or diffuse central serous chorioretinopathy (CSC),by a series of 3 Ranibizumab IVT protocol,and the recurrences frequency at 1 year evolution Methods 9 eyes with focal and /or diffuse CSC. Patients received intravitreous Ranibizumab, 3 times, every 4 weeks in an inductive treatment. The next injections depended on the follow‐up results and were done by series of 3. First and 2 months’ interval follow‐up exam included ETDRS visual acuity (VA), complete ophthalmic examination, fluorescein (FA) and infracyanine (ICG) angiography, and optical coherence tomography (OCT).VA and OCT were done before each IVT. We want to evaluate the incidence of this protocol on the exudation and spot leakage, and on frequency of recurrence and so on the number of IVT needed. Results VA improved in 7 eyes, stabilized in 2. Angiographic leakage reduced about 80% in 8 cases, with resolution of leakage spot in all cases. Choroidal Vessel’s leakage, thickness, dilatation and diameter, reduced significantly at ICG. At OCT, serous retinal detachment disappeared in 7 cases, 80% reduced in 2 cases, pigment epithelial detachment was flattened and less dense in all cases. Most of patients had good functional, anatomical results, with few IVT needed, no scars in the retina. 1serie was enough in 6 cases. This protocol was compared, discussed . Conclusion The results with improved visual acuity,vessel’s leakage and structure normalized at FA and ICG, reduction of exudation at OCT suggest this protocol, with series of 3 Ranibizumab IVT seems effective. It’s possibly a new treatment option for CSC, and it points out the role of choroidal vessel in CSC etiopathogeny